|
References: G
- Gadow, K. D., and A. G. Poling. 1988. Pharmacotherapy and mental retardation. Boston: College Hill Press.
- Gadow, K. D., and J. C. Pomeroy. 1990. A controlled case study of methylphenidate and fenfluramine in a young mentally retarded, hyperactive child. Aus. N.Z. J. Dev. Disabilities 16:323-334.
- Gadow, K. D., J. C. Pomeroy, and E. E. Nolan. 1992. A procedure for monitoring stimulant medication in hyperactive mentally retarded school children. J. Child Adolesc. Psychopharmacol. 2:131-143.
- Gadow, K. D., E. Nolan, J. Sprafkin, and J. S. Verd. 1995. School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: Effects of methylphenidate treatment.
J. Dev. Behav. Pediatr. 16:167-176.
- Garland, E. J., and M. Weiss. 1996. Case study: Obsessive difficult temperament and its response to serotonergic medication. J. Am. Acad. Child Adolesc. Psychiatry 35:916-920.
- Geller, D. A., J. Biederman, E. D. Reed, T. Spencer, and T. E. Wilens. 1995. Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J.
Am. Acad. Child Adolesc. Psychiatry 34:36-44.
- Ghaziuddin, M., and L. Tsai. 1991. Depression in autistic disorder. Br. J. Psychiatry 159:721-723.
- Gillberg, C., J. Wahlstrom, R. Johansson, M. Tornblom, and K. Albertsson-Wikland. 1986. Folic acid as an adjunct in the treatment of children with the autism fragile X syndrome (A FRA X). Dev. Med.
Child Neurol. 28:624-627.
- Gillberg, C., H. Melander, A. L. von Knorring, L. O. Janols, G. Thernlund, B. Hagglof, L. Eidevall-Wallin, P. Gustafsson, and S. Kopp. 1997. Long-term stimulant treatment of children with
attention-deficit hyperactivity disorder symptoms: A randomized, double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 54:857-864.
- Gittelman-Klein, R., and D. F. Klein. 1971. Controlled imipramine treatment of school phobia. Arch. Gen. Psychiatry 25:204-207.
- Glazer, W. M. 1997. Olanzapine and the new generation of antipsychotic agents: Patterns of use. J. Clin. Psychiatry 58:18-21.
- Goldson, E., and R. J. Hagerman. 1993. Fragile X syndrome and failure to thrive. Am. J. Dis. Child. 147:605-607.
- Gordon, C. T., R. C. State, J. E. Nelson, S. D. Hamburger, and J. L. Rapoport. 1993. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch.
Gen. Psychiatry 50:441-447.
- Granger, R., U. Staubli, M. Davis, Y. Perez, L. Nilsson, G. Rogers, and G. Lynch. 1993. A drug that facilitates glutaminergic transmission reduces exploratory activity and improves performance in a
learning-dependent task. Synapse 15:326-329.
- Granger, R., S. Deadwyler, M. Davis, B. Moskovitz, M. Kessler, G. Rogers, and G. Lynch. 1996. Facilitation of glutamate receptors reverses an age associated memory impairment in rats. Synapse
22:332-337.
- Greenblatt, J. M., L. C. Huffman, and A. L. Reiss. 1994. Folic acid in neurodevelopment and child psychiatry. Prog. Neuropsychopharmacol. Bioil. Psychiatry 18:647-660.
- Greendyke, R. M., and D. R. Kanter. 1986. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: A double blind study. J. Clin. Psychiatry 47:423-426.
- Gualtieri, C. T. 1977. Imipramine and children: A review and some speculations about the mechanism of drug action. Dis. Nerv. Syst. 38:368-375.
- ---. 1990. Neuropsychiatry and behavioral pharmacology. Berlin: Springer Verlag.
- ---. 1992. Psychopharmacology and the fragile X syndrome. In R. J. Hagerman and P. McKenzie (eds.), 1992 International Fragile X Conference Proceedings. Dillon, Colo.: National Fragile X Foundation and
Spectra Publishing, pp. 167-178.
- Gualtieri, C. T., R. W. Evans, and D. R. Patterson. 1987. The medical treatment of autistic people: Problems and side effects. In E. Shopler and G. Mesibov (eds.), Neurobiological issues in autism. New
York: Plenum Publishing.
- Gualtieri, C. T., M. Chandler, T. B. Coons, and L. T. Brown. 1989. Amantadine: A new clinical profile for traumatic brain injury. Clin. Neuropharmacol. 12:258-270.
- Gustavson, K. H., K. Dahlblom, A. Flood, G. Holmgren, H. K. Blomquist, and G. Sanner. 1985. Effect of folic acid treatment in fragile X syndrome. Clin. Genet. 27:463-467.
- Gutgesell, H., D. Atkins, R. Barst, M. Buck, W. Franklin, R. Humes, R. Ringel, R. Shaddy, and K. A. Taubert. 1999. AHA Scientific Statement: Cardiovascular monitoring of children and adolescents
receiving psychotropic drugs. J. Am. Acad. Child Adolesc. Psychiatry 38:1047-1050.
|
This article is not intended to give medical advice for individual cases. Any change in medical treatment
should be done in consultation with appropriate medical personnel. This article is written for medical professionals. Some of the terms will be unfamiliar to those who are not trained in medical fields.
*This article is from the chapter on treatment in the 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research edited
by Randi Jenssen Hagerman, M.D. and Paul Hagerman, M.D., Ph.D., to be published May 2002. It is included with permission from The Johns Hopkins University Press. References to other chapters refer to chapters in
the book which are not included as part of this website.
The complete 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research can be ordered from the National Fragile X Foundation by calling
1-800-688-8765 or from The Johns Hopkins University Press at 1-800-537-5487.
|
|
Medical Follow-up Pharmacotherapy Future Prospects
Outline Medications Medical Conditions
References: A, B, C, D, EF, G, H, IJ, K, L, M, NOP, QR, S, T, UVWXYZ
|
